The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020

Paolo A. Ascierto; Michael B. Atkins; Alexander M. Eggermont; Jeffrey E. Gershenwald; Jean Jacques Grob; Omid Hamid; Vernon K. Sondak; Jeffrey A. Sosman; Hussein A. Tawbi; Jeffrey S. Weber; Corrado Caracò; Iman Osman; Igor Puzanov

doi:10.1186/s12967-021-02808-3

The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020

Paolo A. Ascierto, Michael B. Atkins, Alexander M. Eggermont, Jeffrey E. Gershenwald, Jean Jacques Grob, Omid Hamid, Vernon K. Sondak, Jeffrey A. Sosman, Hussein A. Tawbi, Jeffrey S. Weber, Corrado Caracò, Iman Osman, Igor Puzanov

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

The Great Debate session at the 2020 Melanoma Bridge virtual congress (December 3rd–5th, Italy) featured counterpoint views from experts on five specific controversial issues in melanoma. The debates considered whether or not innate immunity is important in the response to cancer and immunotherapy, how useful are the revised American Joint Committee on Cancer (AJCC) classification for the staging of patients, the use of sentinel node biopsy for staging patients, the use of triplet combination of targeted therapy plus immunotherapy versus combined immunotherapy, and the respective benefits of neoadjuvant versus adjuvant therapy. As is usual with Bridge congresses, the debates were assigned by meeting Chairs and positions taken by experts during the debates may not have necessarily reflected their own personal opinion.

Original language	English (US)
Article number	142
Journal	Journal of translational medicine
Volume	19
Issue number	1
DOIs	https://doi.org/10.1186/s12967-021-02808-3
State	Published - Dec 2021

Keywords

Adjuvant
Anti-CTLA-4
Anti-PD-1
BRAF inhibitor
Immunotherapy
MEK inhibitor
Melanoma
Neoadjuvant
Staging
Targeted therapy

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1186/s12967-021-02808-3

Cite this

@article{6752fa0297b0454384678e8ba3cf33a1,

title = "The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020",

abstract = "The Great Debate session at the 2020 Melanoma Bridge virtual congress (December 3rd–5th, Italy) featured counterpoint views from experts on five specific controversial issues in melanoma. The debates considered whether or not innate immunity is important in the response to cancer and immunotherapy, how useful are the revised American Joint Committee on Cancer (AJCC) classification for the staging of patients, the use of sentinel node biopsy for staging patients, the use of triplet combination of targeted therapy plus immunotherapy versus combined immunotherapy, and the respective benefits of neoadjuvant versus adjuvant therapy. As is usual with Bridge congresses, the debates were assigned by meeting Chairs and positions taken by experts during the debates may not have necessarily reflected their own personal opinion.",

keywords = "Adjuvant, Anti-CTLA-4, Anti-PD-1, BRAF inhibitor, Immunotherapy, MEK inhibitor, Melanoma, Neoadjuvant, Staging, Targeted therapy",

author = "Ascierto, {Paolo A.} and Atkins, {Michael B.} and Eggermont, {Alexander M.} and Gershenwald, {Jeffrey E.} and Grob, {Jean Jacques} and Omid Hamid and Sondak, {Vernon K.} and Sosman, {Jeffrey A.} and Tawbi, {Hussein A.} and Weber, {Jeffrey S.} and Corrado Carac{\`o} and Iman Osman and Igor Puzanov",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

doi = "10.1186/s12967-021-02808-3",

language = "English (US)",

volume = "19",

journal = "Journal of translational medicine",

issn = "1479-5876",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - The “Great Debate” at Melanoma Bridge 2020

T2 - December, 5th, 2020

AU - Ascierto, Paolo A.

AU - Atkins, Michael B.

AU - Eggermont, Alexander M.

AU - Gershenwald, Jeffrey E.

AU - Grob, Jean Jacques

AU - Hamid, Omid

AU - Sondak, Vernon K.

AU - Sosman, Jeffrey A.

AU - Tawbi, Hussein A.

AU - Weber, Jeffrey S.

AU - Caracò, Corrado

AU - Osman, Iman

AU - Puzanov, Igor

PY - 2021/12

Y1 - 2021/12

N2 - The Great Debate session at the 2020 Melanoma Bridge virtual congress (December 3rd–5th, Italy) featured counterpoint views from experts on five specific controversial issues in melanoma. The debates considered whether or not innate immunity is important in the response to cancer and immunotherapy, how useful are the revised American Joint Committee on Cancer (AJCC) classification for the staging of patients, the use of sentinel node biopsy for staging patients, the use of triplet combination of targeted therapy plus immunotherapy versus combined immunotherapy, and the respective benefits of neoadjuvant versus adjuvant therapy. As is usual with Bridge congresses, the debates were assigned by meeting Chairs and positions taken by experts during the debates may not have necessarily reflected their own personal opinion.

AB - The Great Debate session at the 2020 Melanoma Bridge virtual congress (December 3rd–5th, Italy) featured counterpoint views from experts on five specific controversial issues in melanoma. The debates considered whether or not innate immunity is important in the response to cancer and immunotherapy, how useful are the revised American Joint Committee on Cancer (AJCC) classification for the staging of patients, the use of sentinel node biopsy for staging patients, the use of triplet combination of targeted therapy plus immunotherapy versus combined immunotherapy, and the respective benefits of neoadjuvant versus adjuvant therapy. As is usual with Bridge congresses, the debates were assigned by meeting Chairs and positions taken by experts during the debates may not have necessarily reflected their own personal opinion.

KW - Adjuvant

KW - Anti-CTLA-4

KW - Anti-PD-1

KW - BRAF inhibitor

KW - Immunotherapy

KW - MEK inhibitor

KW - Melanoma

KW - Neoadjuvant

KW - Staging

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85103997799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85103997799&partnerID=8YFLogxK

U2 - 10.1186/s12967-021-02808-3

DO - 10.1186/s12967-021-02808-3

M3 - Article

C2 - 33827575

AN - SCOPUS:85103997799

SN - 1479-5876

VL - 19

JO - Journal of translational medicine

JF - Journal of translational medicine

IS - 1

M1 - 142

ER -

The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this